Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: Relationship to dementia severity

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 10, Issue 1, 1998, Pages 55-63

  Kaufer, Daniel ^a   Cummings, Jeffrey L ^b   Christine, Dianne ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TACRINE;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANXIETY; APATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; DRUG EFFECT; DYSPHORIA; EUPHORIA; FEMALE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; IRRITABILITY; MALE; NEUROPSYCHIATRY; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 0031917730     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.10.1.55     Document Type: Article

References (51)

1. Cummings JL, Victoroff JI: Noncognitive neuropsychiatric syndromes in Alzheimer's disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1990; 3:140-158
2. Mega MS, Cummings JL, Fiorello T, et al: The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46:130-135
3. Mangone CA, Sanguinetti RM, Baumann PD, et al: Influence of feelings of burden on the caregiver's perception of the patient's functional status. Dementia 1993; 4:287-293
4. Perry EK, Tomlinson BE, Blessed G, et al: Correlation of cholinergic abnormalities with senile plaques and mental test scores in dementia. British Medical Journal 1978; 2:1457-1459
5. Bartus RT, Dean RL III, Beer B, et al: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-417
6. Schneider LS: Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology 1994; 43(suppl 4):S64-S79
7. Eagger SA, Levy R, Sahakian BJ: Tacrine in Alzheimer's disease. Lancet 1991; 337:989-992
8. Knapp MJ, Knopman DS, Solomon PR, et al: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271:985-991
9. Farlow M, Gracon S, Hershey L, et al: A controlled trial of tacrine in Alzheimer's disease: the Tacrine Study Group. JAMA 1992; 268:2523-2528
10. Sunderland T, Tariot PN, Cohen RM, et al: Anticholinergic sensitivity in patients with dementia of the Alzheimer's type and age-matched controls. Arch Gen Psychiatry 1987; 44:418-426
11. Cummings JL, Kaufer DI: Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996; 47:876-883
12. Kaufer DI, Cummings, JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996; 9:1-6
13. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314
14. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-944
15. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
16. Wragg RE, Jeste DV: Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989; 146:577-587
17. Flynn FG, Cummings JL, Gornbein J: Delusions in dementia syndromes: investigation of behavioral and neuropsychological correlates. J Neuropsychiatry Clin Neurosci 1991; 3:364-370
18. Aarsland D, Cummings JL, Yenner G, et al: Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Am J Psychiatry 1996; 153:243-247
19. Cummings JL, Ross W, Absher J, et al: Depressive symptoms in Alzheimer disease: assessment and determinants. Alzheimer Dis Assoc Disord 1995; 2:87-93
20. Cummings JL, Gorman DG, Shapira J: Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993; 33:536-541
21. Gorman DG, Read SR, Cummings JL: Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1993; 6:229-234
22. Perry EK, Marshall E, Kerwin JM, et al: Evidence of a monoaminergic:cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990; 55:1454-1456
23. Cummings JL: Psychosis in neurologic disease: neurobiology and pathogenesis. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1992; 5:144-150
24. Langlais PJ, Thai LJ, Hansen L, et al: Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993; 43:1927-1934
25. Perry EK, Irving D, Kerwin JM, et al: Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993; 7:69-79
26. McCormick DA: Neurotransmitter actions in the thalamus and cerebral cortex and their role in neuromodulation of thalamocortical activity. Prog Neurobiol 1992; 39:337-388
27. Perry EK, Perry RH: Acetykholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995; 28:240-258
28. Liberini P, Valerio A, Memo M, et al: Lewy-body dementia and responsiveness to cholinesterase-inhibitors: a paradigm for heterogeneity in Alzheimer's disease? Trends Pharmacol Sci 1996; 17:155-160
29. McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report on the consortium on DLB international workshop. Neurology 1996; 47:1113-1124
30. Cummings JL: Personality alterations in Alzheimer's disease: assessment and characterization. Bull Clin Neurosci 1989; 54:80-87
31. Kaufer DI, Cummings JL: Personality alterations in degenerative brain disorders, in Neuropsychiatry of Personality Disorders, edited by Ratey J. Cambridge, MA, Blackwell Scientific, 1995, pp 172-209
32. Palmer AM, Stratmann GC, Procter AW, et al: Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol 1988; 23:616-620
33. Marin RS: Differential diagnosis and classification of apathy. Am J Psychiatry 1990; 147:22-30
34. Cummings JL: Frontal-subcortical circuits and human behavior. Arch Neurol 1993; 50:873-880
35. Adem A: Putative mechanisms of action of tacrine in Alzheimer's disease. Acta Neurol Scand Suppl 1992; 139:69-74
36. Zubenko GS, Moossey, Martinez J, et al: Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991; 48:619-624
37. Palmer AM, DeKosky ST: Monoamine neurons in aging and Alzheimer's disease. J Neural Transm [Gen Sect] 1993; 91:135-159
38. Raskind MA, Peskind ER: Neurologic bases of noncognitive behavioral problems in Alzheimer's disease. Alzheimer Dis Assoc Disord 1994; 8(suppl 3):54-60
39. Soininen H, Unni L, Shillcutt S: Effect of acute and chronic cholinesterase inhibition on biogenic amines in rat brain. Neurochem Res 1990; 15:1185-1190
40. Alhainen K, Helkala E-L, Reinikainen K, et al: The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. J Neural Transm [P-D Sect] 1993; 5:185-192
41. Freeman SE, Dawson RM: Tacrine: a pharmacological review. Prog Neurobiol 1991; 36:257-277
42. Soares JC, Gershon S: THA: historical aspects, review of pharmacological properties and therapeutic effects. Dementia 1995; 6:225-234
43. Bierer LM, Haroutunian V, Gabriel, S, et al: Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of cholinergic deficits. J Neurochem 1995; 64:749-760
44. Arnold SE, Hyman BT, Flory J, et al: The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991; 1:103-116
45. Procter AW, Lowe, SL, Palmer AM, et al: Topographical distribution of neurochemical changes in Alzheimer's disease. Brain Res 1988; 14:939-944
46. Alhainen K, Helkala E-L, Riekkinen P: Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer's patients. Dementia 1993; 4:54-58
47. Sahakian BJ, Owen AM, Morant NJ, et al: Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 1993; 110:395-401
48. Craig AH, Cummings JL, Fairbanks L, et al: Cerebral blood flow correlates of apathy in Alzheimer's disease. Arch Neurol 1996; 53:1116-1120
49. Sultzer DL, Mahler ME, Mandelkern MA, et al: The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1995; 7:476-484
50. Poirier J, Delisle MC, Quirion R, et al: Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Nat Acad Sci USA 1995; 92:12260-12264
51. Soininen H, Kosunen O, Helisalmi S, et al: A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer's patients carrying apolipoprotein epsilon 4 allele. Neurosci Lett 1995; 187:79-82